Madison Muller

Person

Mentions

Episodes

Claims

Madison Muller, mentioned 24 times across podcast episodes and expert conversations analyzed by Sonic.

What Madison Muller has said

Madison Mueller of Bloomberg News assesses that Novo Nordisk has been caught "flat-footed" by the rapid growth of the obesity drug market and is struggling to fill its product pipeline.

bearish·Madison Mueller

Eli Lilly launched a direct-to-consumer website that reduced the price of its obesity drugs for patients paying with cash.

bullish·Madison Mueller

Novo Nordisk has lost significant market share to Eli Lilly in the weight loss drug market over the past two years.

bearish·Madison Mueller

Madison Mueller of Bloomberg News assesses that Novo Nordisk has been caught "flat-footed" by the rapid growth of the obesity drug market and is struggling to fill its product pipeline.

Expert perspectiveMadison MuellerMay 26

Eli Lilly launched a direct-to-consumer website that reduced the price of its obesity drugs for patients paying with cash.

Expert perspectiveMadison MuellerJul 21

Novo Nordisk has lost significant market share to Eli Lilly in the weight loss drug market over the past two years.

Expert perspectiveMadison MuellerJul 21

Novo Nordisk's lawsuit alleges Eli Lilly's advertising is misleading because it uses data from trials of an older, lower dose of Wegovy, not the recently approved higher dose.

Expert perspectiveMadison MuellerJul 21

Medicare has opened access to obesity drugs for its beneficiaries for the first time.

Expert perspectiveMadison MuellerJul 21

Some large employers have recently withdrawn insurance coverage for obesity drugs due to their high cost.

Expert perspectiveMadison MuellerJul 21

There is a widespread consumer perception that Eli Lilly's Zepbound is more effective than Novo Nordisk's Wegovy.

Expert perspectiveMadison MuellerJul 21

The Trump administration is supportive of psychedelic medicines and has recently taken steps to reduce research restrictions on these compounds.

Expert perspectiveMadison MullerJul 16

The U.S. government has opened Medicare coverage for weight loss drugs, which is expected to significantly boost demand.

Expert perspectiveMadison MullerJul 16

Compass Pathways is expected to be the first company in the psychedelic medicine space to get FDA approval for its treatment.

Expert perspectiveMadison MullerJul 16

Eli Lilly has spent over $20 billion on M&A this year.

Expert perspectiveMadison MullerJul 16

While users claim black market peptides are life-changing, there is no rigorous safety or effectiveness data to support these claims.

Expert perspectiveMadison MuellerJun 27

An FDA committee will meet in July to review the evidence and data surrounding unapproved peptides.

Expert perspectiveMadison MuellerJun 27

While users of black market peptides report life-changing effects, there is no rigorous scientific evidence, safety data, or effectiveness data to support these anecdotal claims.

Expert perspectiveMadison MuellerJun 24

Eli Lilly became the first healthcare company to achieve a trillion-dollar market capitalization in the previous year.

Expert perspectiveMadison MuellerMay 27

Access to obesity drugs for Medicare beneficiaries is scheduled to be expanded in July.

Expert perspectiveMadison MuellerMay 27

The current Ebola virus strain circulating in the Democratic Republic of the Congo and Uganda has no known effective treatments or vaccines.

Expert perspectiveMadison MuellerMay 27

Eli Lilly hired former FDA official Peter Marks last year to lead its infectious diseases unit.

Expert perspectiveMadison MuellerMay 27

Eli Lilly is pursuing acquisitions to build its next phase of growth in anticipation of its current blockbuster drugs losing patent protection.

Expert perspectiveMadison MuellerMay 26

Eli Lilly hired former FDA official Peter Marks last year to lead its infectious disease unit.

Expert perspectiveMadison MuellerMay 26

Create a free account to see Madison Muller's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail